Novartis shares dropped over 12.5% after its Phase 3 HARBOR trial for del-desiran and Phase 3 HORIZON trial for pelacarsen both failed to meet primary endpoints. These failures mean the drugs did not show significant benefits over placebo for their targeted conditions, impacting investor confidence. A securities law investigation has been launched to examine if Novartis made misleading statements about these drug programs. Investors who suffered losses are encouraged to review their options with legal counsel.
Novartis' failed cholesterol drug trial for pelacarsen caused a sharp 14% drop in its stock and dragged down the entire Lp(a) drug class, hitting Amgen hardest with a 10% decline despite Amgen's positive Phase 3 lung cancer trial results announced th...
Novartis shares fell up to 10% after its drug del-desiran failed to meet the primary endpoint in the Phase 3 HARBOR study for myotonic dystrophy type 1, showing no significant improvement over placebo. This setback follows another recent late-stage t...
Novartis shares fell sharply following the failure of its late-stage drug candidates pelacarsen and del-desiran in phase 3 trials, which impacts the company’s near-term growth prospects. Despite these setbacks, Novartis reaffirmed its revenue growth ...
Novartis announced that its drug pelacarsen, designed to lower the harmful cholesterol Lp(a), failed to significantly reduce cardiovascular events in a late-stage trial. This setback raises doubts about the effectiveness of targeting Lp(a) to prevent...
